Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 1
2012 1
2013 2
2014 2
2017 1
2019 4
2020 3
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Editorial: Approaches to Advance Cancer Vaccines to Clinical Utility.
Van Nuffel AMT, Boudousquié C, Tuyaerts S. Van Nuffel AMT, et al. Among authors: boudousquie c. Front Immunol. 2019 Aug 27;10:2032. doi: 10.3389/fimmu.2019.02032. eCollection 2019. Front Immunol. 2019. PMID: 31507617 Free PMC article. No abstract available.
Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment.
Gannon PO, Harari A, Auger A, Murgues C, Zangiacomi V, Rubin O, Ellefsen Lavoie K, Guillemot L, Navarro Rodrigo B, Nguyen-Ngoc T, Rusakiewicz S, Rossier L, Boudousquié C, Baumgaertner P, Zimmermann S, Trueb L, Iancu EM, Sempoux C, Demartines N, Coukos G, Kandalaft LE. Gannon PO, et al. Among authors: boudousquie c. Cytotherapy. 2020 Dec;22(12):780-791. doi: 10.1016/j.jcyt.2020.07.011. Epub 2020 Oct 14. Cytotherapy. 2020. PMID: 33069566
A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma.
Harari A, Sarivalasis A, de Jonge K, Thierry AC, Huber F, Boudousquie C, Rossier L, Orcurto A, Imbimbo M, Baumgaertner P, Bassani-Sternberg M, Kandalaft LE. Harari A, et al. Among authors: boudousquie c. Cancers (Basel). 2021 Nov 18;13(22):5801. doi: 10.3390/cancers13225801. Cancers (Basel). 2021. PMID: 34830955 Free PMC article.
MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer.
Dudda JC, Salaun B, Ji Y, Palmer DC, Monnot GC, Merck E, Boudousquie C, Utzschneider DT, Escobar TM, Perret R, Muljo SA, Hebeisen M, Rufer N, Zehn D, Donda A, Restifo NP, Held W, Gattinoni L, Romero P. Dudda JC, et al. Among authors: boudousquie c. Immunity. 2013 Apr 18;38(4):742-53. doi: 10.1016/j.immuni.2012.12.006. Immunity. 2013. PMID: 23601686 Free PMC article.
A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
Sarivalasis A, Boudousquié C, Balint K, Stevenson BJ, Gannon PO, Iancu EM, Rossier L, Martin Lluesma S, Mathevet P, Sempoux C, Coukos G, Dafni U, Harari A, Bassani-Sternberg M, Kandalaft LE. Sarivalasis A, et al. Among authors: boudousquie c. J Transl Med. 2019 Nov 26;17(1):391. doi: 10.1186/s12967-019-02133-w. J Transl Med. 2019. PMID: 31771601 Free PMC article.
16 results